BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Menichetti F, Popoli P, Puopolo M, Spila Alegiani S, Tiseo G, Bartoloni A, De Socio GV, Luchi S, Blanc P, Puoti M, Toschi E, Massari M, Palmisano L, Marano G, Chiamenti M, Martinelli L, Franchi S, Pallotto C, Suardi LR, Luciani Pasqua B, Merli M, Fabiani P, Bertolucci L, Borchi B, Modica S, Moneta S, Marchetti G, d'Arminio Monforte A, Stoppini L, Ferracchiato N, Piconi S, Fabbri C, Beccastrini E, Saccardi R, Giacometti A, Esperti S, Pierotti P, Bernini L, Bianco C, Benedetti S, Lanzi A, Bonfanti P, Massari M, Sani S, Saracino A, Castagna A, Trabace L, Lanza M, Focosi D, Mazzoni A, Pistello M, Falcone M; TSUNAMI Study group. Effect of High-Titer Convalescent Plasma on Progression to Severe Respiratory Failure or Death in Hospitalized Patients With COVID-19 Pneumonia: A Randomized Clinical Trial. JAMA Netw Open 2021;4:e2136246. [PMID: 34842924 DOI: 10.1001/jamanetworkopen.2021.36246] [Cited by in Crossref: 27] [Cited by in F6Publishing: 30] [Article Influence: 13.5] [Reference Citation Analysis]
Number Citing Articles
1 Iannizzi C, Chai KL, Piechotta V, Valk SJ, Kimber C, Monsef I, Wood EM, Lamikanra AA, Roberts DJ, McQuilten Z, So-Osman C, Jindal A, Cryns N, Estcourt LJ, Kreuzberger N, Skoetz N. Convalescent plasma for people with COVID-19: a living systematic review. Cochrane Database Syst Rev 2023;2:CD013600. [PMID: 36734509 DOI: 10.1002/14651858.CD013600.pub5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
2 Senefeld JW, Gorman EK, Johnson PW, Moir ME, Klassen SA, Carter RE, Paneth NS, Sullivan DJ, Morkeberg OH, Wright RS, Fairweather D, Bruno KA, Shoham S, Bloch EM, Focosi D, Henderson JP, Juskewitch JE, Pirofski L, Grossman BJ, Tobian AA, Franchini M, Ganesh R, Hurt RT, Kay NE, Parikh SA, Baker SE, Buchholtz ZA, Buras MR, Clayburn AJ, Dennis JJ, Diaz Soto JC, Herasevich V, Klompas AM, Kunze KL, Larson KF, Mills JR, Regimbal RJ, Ripoll JG, Sexton MA, Shepherd JR, Stubbs JR, Theel ES, van Buskirk CM, van Helmond N, Vogt MN, Whelan ER, Wiggins CC, Winters JL, Casadevall A, Joyner MJ. Mortality rates among hospitalized patients with COVID-19 treated with convalescent plasma A Systematic review and meta-analysis.. [DOI: 10.1101/2023.01.11.23284347] [Reference Citation Analysis]
3 Tiseo G, Barbieri C, Galfo V, Occhineri S, Matucci T, Almerigogna F, Kalo J, Sponga P, Cesaretti M, Marchetti G, Forniti A, Caroselli C, Ferranti S, Pogliaghi M, Polidori M, Fabiani S, Verdenelli S, Tagliaferri E, Riccardi N, Suardi LR, Carmignani C, Batini S, Puccetti L, Iapoce R, Menichetti F, Falcone M. Efficacy and Safety of Nirmatrelvir/Ritonavir, Molnupiravir, and Remdesivir in a Real-World Cohort of Outpatients with COVID-19 at High Risk of Progression: The PISA Outpatient Clinic Experience. Infect Dis Ther 2023;12:257-71. [PMID: 36441485 DOI: 10.1007/s40121-022-00729-2] [Reference Citation Analysis]
4 Deng J, Heybati K, Ramaraju HB, Zhou F, Rayner D, Heybati S. Differential efficacy and safety of anti-SARS-CoV-2 antibody therapies for the management of COVID-19: a systematic review and network meta-analysis. Infection 2023;51:21-35. [PMID: 35438413 DOI: 10.1007/s15010-022-01825-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
5 Manzini PM, Ciccone G, De Rosa FG, Cavallo R, Ghisetti V, D'Antico S, Galassi C, Saccona F, Castiglione A, Birocco N, Francisci T, Hu H, Pecoraro C, Danielle F, Labanca L, Bordiga AM, Lorenzi M, Camisasca G, Giachino O, Pagliarino M, Ottone P, Scuvera ITD, Guaschino R, Freilone R, Berti P, Pittaluga F, Avolio M, Costa C, Raso S, Nucci A, Milan M, Baffa A, Russo A, Tornello A, Maddalena L, Delios G, Marletto FP, De Micheli AG, Mattei A, Baldassano S, Canta F, Russo ML, Bergamo D, Vitale F, Liccardi MM, Chinaglia A, Calcagno A, Converso M, Aldieri C, Libanore V, Blangetti I, Benedetti V, Mitola B, Scozzari G; PLACO COVID Study Group. Convalescent or standard plasma versus standard of care in the treatment of COVID-19 patients with respiratory impairment: short and long-term effects. A three-arm randomized controlled clinical trial. BMC Infect Dis 2022;22:879. [PMID: 36418984 DOI: 10.1186/s12879-022-07716-5] [Reference Citation Analysis]
6 Kimber C, Lamikanra AA, Geneen LJ, Sandercock J, Dorée C, Valk SJ, Estcourt LJ. A systematic review of the safety and efficacy of convalescent plasma or immunoglobulin treatment for people with severe respiratory viral infections due to coronaviruses or influenza. Transfusion Medicine 2022. [DOI: 10.1111/tme.12942] [Reference Citation Analysis]
7 Kiss-Dala N, Szabo BG, Lakatos B, Reti M, Szlavik J, Valyi-Nagy I. Use of convalescent plasma therapy in hospitalised adult patients with non-critical COVID-19: a focus on the elderly from Hungary. Geroscience 2022;44:2427-45. [PMID: 36367599 DOI: 10.1007/s11357-022-00683-4] [Reference Citation Analysis]
8 Bartelt LA, Markmann AJ, Nelson B, Keys J, Root H, Henderson HI, Kuruc J, Baker C, Bhowmik DR, Hou YJ, Premkumar L, Cornaby C, Schmitz JL, Weiss S, Park Y, Baric R, de Silva AM, Lachiewicz A, Napravnik S, van Duin D, Margolis DM. Outcomes of Convalescent Plasma with Defined High versus Lower Neutralizing Antibody Titers against SARS-CoV-2 among Hospitalized Patients: CoronaVirus Inactivating Plasma (CoVIP) Study. mBio 2022;:e0175122. [PMID: 36135380 DOI: 10.1128/mbio.01751-22] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
9 Gachoud D, Pillonel T, Tsilimidos G, Battolla D, Dumas D, Opota O, Fontana S, Vollenweider P, Manuel O, Greub G, Bertelli C, Rufer N. Antibody response and intra-host viral evolution after plasma therapy in COVID-19 patients pre-exposed or not to B-cell-depleting agents. Br J Haematol 2022. [PMID: 36101920 DOI: 10.1111/bjh.18450] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
10 Zhou CK, Bennett MM, Villa CH, Hammonds KP, Lu Y, Ettlinger J, Priest EL, Gottlieb RL, Davis S, Mays E, Clarke TC, Shoaibi A, Wong H, Anderson SA, Kelly RJ. Multi-center matched cohort study of convalescent plasma for hospitalized patients with COVID-19. PLoS ONE 2022;17:e0273223. [DOI: 10.1371/journal.pone.0273223] [Reference Citation Analysis]
11 Estcourt LJ, Cohn CS, Pagano MB, Iannizzi C, Kreuzberger N, Skoetz N, Allen ES, Bloch EM, Beaudoin G, Casadevall A, Devine DV, Foroutan F, Gniadek TJ, Goel R, Gorlin J, Grossman BJ, Joyner MJ, Metcalf RA, Raval JS, Rice TW, Shaz BH, Vassallo RR, Winters JL, Tobian AAR. Clinical Practice Guidelines From the Association for the Advancement of Blood and Biotherapies (AABB): COVID-19 Convalescent Plasma. Ann Intern Med 2022. [PMID: 35969859 DOI: 10.7326/M22-1079] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
12 Mathur P, Kottilil S. Immunomodulatory therapies for COVID-19. Front Med 2022;9. [DOI: 10.3389/fmed.2022.921452] [Reference Citation Analysis]
13 Boonyaratanakornkit J, Boeckh M, Waghmare A. Monoclonal antibodies for prophylaxis and treatment of respiratory viral infections. Curr Opin Infect Dis 2022;35:280-7. [PMID: 35849517 DOI: 10.1097/QCO.0000000000000846] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Qian Z, Zhang Z, Ma H, Shao S, Kang H, Tong Z. The efficiency of convalescent plasma in COVID-19 patients: A systematic review and meta-analysis of randomized controlled clinical trials. Front Immunol 2022;13:964398. [DOI: 10.3389/fimmu.2022.964398] [Reference Citation Analysis]
15 Benites BD, Costa-Lima C, Pinto FBR, da Costa VA, Duarte ADSS, Zangirolami AB, Amaro EC, Granja F, Proenca-Modena JL, Saad STO, Addas-Carvalho M. Selection of plasma donors for the production of anti-SARS-CoV-2 immunoglobulin-based therapies: Strategies for quantitative antibody measurements. Transfus Apher Sci 2022;:103513. [PMID: 35871137 DOI: 10.1016/j.transci.2022.103513] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Spinicci M, Mazzoni A, Coppi M, Antonelli A, Salvati L, Maggi L, Basile G, Graziani L, Di Lauria N, Di Pilato V, Kiros ST, Beccastrini E, Saccardi R, Angileri M, Cecchi M, Cusi MG, Rossolini GM, Annunziato F, Bartoloni A, Parronchi P. Long-term SARS-CoV-2 Asymptomatic Carriage in an Immunocompromised Host: Clinical, Immunological, and Virological Implications. J Clin Immunol 2022. [PMID: 35779200 DOI: 10.1007/s10875-022-01313-6] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
17 Franchini M, Focosi D, Percivalle E, Beccaria M, Garuti M, Arar O, Pecoriello A, Spreafico F, Greco G, Bertacco S, Ghirardini M, Santini T, Schiavulli M, Stefania M, Gagliardo T, Sammartino JC, Ferrari A, Zani M, Ballotari A, Glingani C, Baldanti F. Variant of Concern-Matched COVID-19 Convalescent Plasma Usage in Seronegative Hospitalized Patients. Viruses 2022;14:1443. [DOI: 10.3390/v14071443] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Puopolo M, Morciano C, Buoncervello M, De Nuccio C, Potenza RL, Toschi E, Palmisano L. Drugs and convalescent plasma therapy for COVID-19: a survey of the interventional clinical studies in Italy after 1 year of pandemic. Trials 2022;23:527. [PMID: 35733167 DOI: 10.1186/s13063-022-06474-8] [Reference Citation Analysis]
19 Metcalf RA, Cohn CS, Allen ES, Bakhtary S, Gniadek T, Gupta G, Harm S, Haspel R, Hess A, Jacobson J, Lokhandwala PM, Murphy C, Poston J, Prochaska MT, Raval JS, Saifee NH, Salazar E, Shan H, Zantek N, Pagano MB. Current advances in transfusion medicine 2021: A critical review of selected topics by the AABB Clinical Transfusion Medicine Committee. Transfusion 2022. [PMID: 35713186 DOI: 10.1111/trf.16944] [Reference Citation Analysis]
20 Belov A, Huang Y, Villa CH, Whitaker BI, Forshee R, Anderson SA, Eder A, Verdun N, Joyner MJ, Wright SR, Carter RE, Hung DT, Homer M, Hoffman C, Lauer M, Marks P; Broad Institute COVID-19 Antibody Team. Early administration of COVID-19 convalescent plasma with high titer antibody content by live viral neutralization assay is associated with modest clinical efficacy. Am J Hematol 2022;97:770-9. [PMID: 35303377 DOI: 10.1002/ajh.26531] [Reference Citation Analysis]
21 Song ATW, Rocha V, Mendrone-Júnior A, Calado RT, De Santis GC, Benites BD, Costa-Lima C, Vargas T, Marques LS, Fernandes JC, Breda FC, Wendel S, Fachini R, Rizzo LV, Kutner JM, Avelino-Silva VI, Machado RRG, Durigon EL, Chevret S, Kallas EG. Treatment of severe COVID-19 patients with either low- or high-volume of convalescent plasma versus standard of care: A multicenter Bayesian randomized open-label clinical trial (COOP-COVID-19-MCTI). Lancet Reg Health Am 2022;10:100216. [PMID: 35308034 DOI: 10.1016/j.lana.2022.100216] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Bartelt LA, Markmann AJ, Nelson B, Keys J, Root H, Henderson HI, Kuruc J, Baker C, Bhowmik DR, Hou YJ, Premkumar L, Cornaby C, Schmitz JL, Weiss S, Park Y, Baric R, de Silva AM, Lachiewicz A, Napravnik S, van Duin D, Margolis DM. Outcomes of convalescent plasma with defined high- versus lower-neutralizing antibody titers against SARS-CoV-2 among hospitalized patients: CoronaVirus Inactivating Plasma (CoVIP), double-blind phase 2 study.. [DOI: 10.1101/2022.04.29.22274387] [Reference Citation Analysis]
23 Gachoud D, Pillonel T, Gerasimos T, Battola D, Dumas D, Opota O, Fontana S, Vollenweider P, Manuel O, Greub G, Bertelli C, Rufer N. Antibody response and intra-host viral evolution after plasma therapy in COVID-19 patients pre-exposed or not to B-cell depleting agents.. [DOI: 10.1101/2022.04.24.22274200] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Alfano G, Morisi N, Frisina M, Ferrari A, Fontana F, Tonelli R, Franceschini E, Meschiari M, Donati G, Guaraldi G. Awaiting a cure for COVID-19: therapeutic approach in patients with different severity levels of COVID-19. Infez Med 2022;30:11-21. [PMID: 35350263 DOI: 10.53854/liim-3001-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Focosi D, Franchini M, Pirofski LA, Burnouf T, Paneth N, Joyner MJ, Casadevall A. COVID-19 Convalescent Plasma and Clinical Trials: Understanding Conflicting Outcomes. Clin Microbiol Rev 2022;:e0020021. [PMID: 35262370 DOI: 10.1128/cmr.00200-21] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 18.0] [Reference Citation Analysis]
26 Prendki V, Tiseo G, Falcone M. Caring for older adults during the COVID-19 pandemic. Clinical Microbiology and Infection 2022. [DOI: 10.1016/j.cmi.2022.02.040] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
27 Paneth NS, Joyner MJ, Casadevall A. The fossilization of randomized clinical trials. J Clin Invest 2022;132:e158499. [PMID: 35166241 DOI: 10.1172/JCI158499] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
28 Franchini M, Focosi D, Casadevall A, Joyner MJ, Perotti C. Convalescent plasma for COVID-19. TSUNAMI is not the final word. Eur J Intern Med 2022:S0953-6205(22)00016-4. [PMID: 35031215 DOI: 10.1016/j.ejim.2022.01.016] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
29 . Error in Article Information. JAMA Netw Open 2022;5:e2146944. [PMID: 35040974 DOI: 10.1001/jamanetworkopen.2021.46944] [Reference Citation Analysis]
30 . Errors in Results, Figure 1, Table 1, and Article Information. JAMA Netw Open 2021;4:e2144236. [PMID: 34932111 DOI: 10.1001/jamanetworkopen.2021.44236] [Reference Citation Analysis]
31 Menichetti F, Falcone M, Tiseo G. Management of COVID patients with convalescent plasma: Do we have the final word? Eur J Intern Med 2021:S0953-6205(21)00368-X. [PMID: 34895816 DOI: 10.1016/j.ejim.2021.10.029] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]